|
Oct 10
|
ASX Growth Companies With High Insider Ownership In October 2024
|
|
Oct 9
|
3 ASX Growth Companies With Insider Ownership Up To 37%
|
|
Oct 9
|
3 ASX Growth Stocks With Insider Ownership Up To 36%
|
|
Oct 8
|
Exploring High Growth Tech Stocks In Australia
|
|
Oct 8
|
3 ASX Growth Stocks Insiders Own With Up To 45% Revenue Growth
|
|
Oct 8
|
ASX Growth Companies With High Insider Ownership For October 2024
|
|
Oct 7
|
3 High Growth Tech Stocks in Australia to Watch
|
|
Oct 7
|
3 ASX Growth Stocks With High Insider Ownership
|
|
Oct 7
|
3 ASX Growth Companies With High Insider Ownership And Up To 60% Earnings Growth
|
|
Oct 6
|
Exploring Three High Growth Tech Stocks In Australia
|
|
Oct 6
|
3 ASX Growth Companies Insiders Are Investing In
|
|
Jul 31
|
Mesoblast Insiders Land Bargain With Gains Of US$58m
|
|
Jul 31
|
Appendix 4C Quarterly Activity Report for Quarter Ended June 30, 2024
|
|
Jul 23
|
FDA accepts Mesoblast’s latest BLA for paediatric GvHD cell therapy
|
|
Jan 5
|
Mesoblast Limited (MESO) Loses -5.45% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
|
|
Dec 21
|
5 Stocks to Ride the Santa Claus Rally
|
|
Nov 26
|
Mesoblast Files for Orphan Drug and Pediatric Rare Disease Designations for Rexlemestrocel-L as Treatment for Severe Congenital Heart Disease
|
|
Apr 28
|
Appendix 4C Quarterly Activity Report
|